Vascular endothelial growth factor inhibition in uveitis: A systematic review

British Journal of Ophthalmology

Volumn 95, Issue 2, 2011, Pages 162-165

  Gulati, Nishi ^a   Forooghian, Farzin ^a   Lieberman, Ronni ^a   Jabs, Douglas A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; RANIBIZUMAB; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

DIABETIC RETINOPATHY; EALES DISEASE; FOLLOW UP; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW (TOPIC); UVEITIS; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; MACULAR EDEMA; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79251497357     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.177279     Document Type: Review

References (58)

1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
3. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72, e5.
4. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90. (Pubitemid 44197628)
5. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 2009;116:2175-81.
6. Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009;116:1488-97, 97 e1.
7. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695, e1-15.
8. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-6.
9. Schaal KB, Hoeh AE, Scheuerle A, et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009;19:613-17.
10. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-9.
11. Arevalo JF, Maia M, Garcia-Amaris RA, et al. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology 2009;116:1481-7, 7 e1.
12. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513.
13. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
14. Huang S, Robinson JB, Deguzman A, et al. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000;60:5334-9.
15. Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res 2007;84:812-22.
16. Sola-Villa D, Camacho M, Sola R, et al. IL-1beta induces VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR pathway in renal mesangial cells. Kidney Int 2006;70:1935-41. (Pubitemid 44863381)
17. Cha HS, Bae EK, Koh JH, et al. Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes. J Rheumatol 2007;34:16-19.
18. Cohen T, Nahari D, Cerem LW, et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-41.
19. Li M, Zhang Y, Feurino LW, et al. Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer Sci 2008;99:733-7.
20. Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001;132:794-6.
21. Roh MI, Kim HS, Song JH, et al. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment. Retina 2009;29:523-9.
22. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
23. Jermak CM, Dellacroce JT, Heffez J, et al. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007;52:503-22.
24. Kim YH, Chung IY, Choi MY, et al. Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia. Neurobiol Dis 2007;26:569-76.
25. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008;14:6371-5.
26. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6.
27. Forooghian F, Kertes PJ, Eng KT, et al. Alterations in the intraocular cytokine milieu following intravitreal bevacizumab. Invest Ophthalmol Vis Sci. [Epud ahead of print].
28. Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye 2009;23:1812-18.
29. Mackensen F, Heinz C, Becker MD, et al. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 2008;28:41-5.
30. Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009;148:303-9, e2.
31. Al-Dhibi H, Khan AO. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS 2009;13:400-2.
32. Ziemssen F, Deuter CM, Stuebiger N, et al. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 2007;245:917-8.
33. Cordero Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:1574-9, e1.
34. Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ, et al. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol 2009;19:622-9.
35. Mirshahi A, Namavari A, Djalilian A, et al. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behcet disease. Ocul Immunol Inflamm 2009;17:59-64.
36. Lott MN, Schiffman JC, Davis JL. Bevacizumab in inflammatory eye disease. Am J Ophthalmol 2009;148:711-7, e2.
37. Jabs DA. Improving the reporting of clinical case series. Am J Ophthalmol 2005;139:900-5.
38. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 2002;10:239-46.
39. Neri P, Mariotti C, Cimino L, et al. Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil. Int Ophthalmol 2009;29:127-33.
40. Thorne JE, Wittenberg S, Jabs DA, et al. Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity. Ophthalmology 2006;113:2310-16.
41. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
42. Chan WM, Lai TY, Liu DT, et al. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007;143:977-83.
43. Wu L, Evans T, Saravia M, et al. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol 2009;53:57-60.
44. Kurup S, Lew J, Byrnes G, et al. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmol 2009;87:349-52.
45. Fine HF, Zhitomirsky I, Freund KB, et al. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis. Retina 2009;29:8-12.
46. Doctor PP, Bhat P, Sayed R, et al. Intravitreal bevacizumab for uveitic choroidal neovascularization. Ocul Immunol Inflamm 2009;17:118-26.
47. Tran TH, Fardeau C, Terrada C, et al. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 2008;246:1685-92.
48. Adan A, Mateo C, Navarro R, et al. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007;27:1180-6.
49. Chang LK, Spaide RF, Brue C, et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008;126:941-5.
50. Mansour AM, Arevalo JF, Ziemssen F, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2009;148:310-6, e2.
51. Mansour AM, Mackensen F, Arevalo JF, et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2008;146:410-16.
52. Dees C, Arnold JJ, Forrester JV, et al. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol 1998;116:1456-61.
53. Flaxel CJ, Owens SL, Mulholland B, et al. The use of corticosteroids for choroidal neovascularisation in young patients. Eye 1998;12(Pt 2):266-72.
54. Neri P, Manoni M, Fortuna C, et al. Association of systemic steroids and mycophenolate mofetil as rescue therapy for uveitic choroidal neovascularization unresponsive to the traditional immunesuppressants: interventional case series. Int Ophthalmol 2009 Sep 2. [Epud ahead of print].
55. Chanana B, Azad RV, Patwardhan S. Role of intravitreal bevacizumab in the management of Eales' disease. Int Ophthalmol 2010;30:57-61.
56. Kucukerdonmez C, Akova YA, Yilmaz G. Intravitreal injection of bevacizumab in Eales disease. Ocul Immunol Inflamm 2008;16:63-5.
57. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-16.
58. Shünemann HJ, Oxman AD, Vist GE Jr, et al. Interpreting results and drawing conclusions. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley, 2008:391-32.